Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

Nab-paclitaxel is as effective as cisplatin but safer for early-stage cervical cancer treatment.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.

The combination therapy is effective and well-tolerated for treating esophageal cancer.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.

Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Tazarotene gel may be more effective for acne than adapalene gel.